Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in serious adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus may leads to higher clinical improvement compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes clinical remission compared with ciclosporin (very low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes clinical improvement compared with ciclosporin (very low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in clinical remission compared with beclometasone (low certainty).
1 finding from 1 review
Intervention not reported
Failure of re‐epithelialisation by day 21 post‐injury Image analysis of digital photographs · people with moderate acute ocular burns
It is very uncertain whether the intervention changes failure of re‐epithelialisation by day 21 post‐injury Image analysis… (very low certainty).
1 finding from 1 review
Intervention not reported
**Visual acuity at final · people with moderate acute ocular burns
1 finding from 1 review
Intervention not reported
Corneal neovascularisation Number of quadrants affected · people with moderate acute ocular burns
It is very uncertain whether the intervention changes corneal neovascularisation Number of quadrants affected (very low certainty).
1 finding from 1 review
Intervention not reported
Symblepharon Presence of symblepharon · people with moderate acute ocular burns
It is very uncertain whether the intervention changes symblepharon Presence of symblepharon (very low certainty).
1 finding from 1 review
Intervention not reported
Time‐to‐epithelialisation (days) · people with moderate acute ocular burns
1 finding from 1 review
Intervention not reported
Adverse effects · people with moderate acute ocular burns
1 finding from 1 review
Intervention not reported
Pain intensity (self‐rated) · people with dementia and mild to moderate pain
1 finding from 1 review
Intervention not reported
Pain intensity (proxy‐rated) · people with dementia and mild to moderate pain
1 finding from 1 review
Intervention not reported
Challenging behaviour · people with dementia and mild to moderate pain
1 finding from 1 review
Intervention not reported
Number of people with adverse events · people with dementia and mild to moderate pain
1 finding from 1 review